Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. 2002

Enrico Sanna, and Fabio Busonero, and Giuseppe Talani, and Mario Carta, and Federico Massa, and Michela Peis, and Elisabetta Maciocco, and Giovanni Biggio
Department of Experimental Biology B Loddo, Section of Neuroscience, University of Cagliari, Cittadella Universitaria, Italy. esanna@unica.it

The pyrazolopyrimidine zaleplon is a hypnotic agent that acts at the benzodiazepine recognition site of GABA(A) receptors. Zaleplon, like the hypnotic agent zolpidem but unlike classical benzodiazepines, exhibits preferential affinity for type I benzodiazepine (BZ(1)/omega(1)) receptors in binding assays. The modulatory action of zaleplon at GABA(A) receptors has now been compared with those of zolpidem and the triazolobenzodiazepine triazolam. Zaleplon potentiated GABA-evoked Cl(-) currents in Xenopus oocytes expressing human GABA(A) receptor subunits with a potency that was higher at alpha1beta2gamma2 receptors than at alpha2- or alpha3-containing receptors. Zolpidem, but not triazolam, also exhibited selectivity for alpha1-containing receptors. However, the potency of zaleplon at these various receptors was one-third to one-half that of zolpidem. Zaleplon and zolpidem also differed in their actions at receptors containing the alpha5 or gamma3 subunit. Zaleplon, zolpidem, and triazolam exhibited similar patterns of efficacy among the different receptor subtypes. The affinities of zaleplon for [(3)H]flunitrazepam or t-[(35)S]butylbicyclophosphorothionate ([(35)S]TBPS) binding sites in rat brain membranes were lower than those of zolpidem or triazolam. Furthermore, zaleplon, unlike zolpidem, exhibited virtually no affinity for the peripheral type of benzodiazepine receptor.

UI MeSH Term Description Entries
D008297 Male Males
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011963 Receptors, GABA-A Cell surface proteins which bind GAMMA-AMINOBUTYRIC ACID and contain an integral membrane chloride channel. Each receptor is assembled as a pentamer from a pool of at least 19 different possible subunits. The receptors belong to a superfamily that share a common CYSTEINE loop. Benzodiazepine-Gaba Receptors,GABA-A Receptors,Receptors, Benzodiazepine,Receptors, Benzodiazepine-GABA,Receptors, Diazepam,Receptors, GABA-Benzodiazepine,Receptors, Muscimol,Benzodiazepine Receptor,Benzodiazepine Receptors,Benzodiazepine-GABA Receptor,Diazepam Receptor,Diazepam Receptors,GABA(A) Receptor,GABA-A Receptor,GABA-A Receptor alpha Subunit,GABA-A Receptor beta Subunit,GABA-A Receptor delta Subunit,GABA-A Receptor epsilon Subunit,GABA-A Receptor gamma Subunit,GABA-A Receptor rho Subunit,GABA-Benzodiazepine Receptor,GABA-Benzodiazepine Receptors,Muscimol Receptor,Muscimol Receptors,delta Subunit, GABA-A Receptor,epsilon Subunit, GABA-A Receptor,gamma-Aminobutyric Acid Subtype A Receptors,Benzodiazepine GABA Receptor,Benzodiazepine Gaba Receptors,GABA A Receptor,GABA A Receptor alpha Subunit,GABA A Receptor beta Subunit,GABA A Receptor delta Subunit,GABA A Receptor epsilon Subunit,GABA A Receptor gamma Subunit,GABA A Receptor rho Subunit,GABA A Receptors,GABA Benzodiazepine Receptor,GABA Benzodiazepine Receptors,Receptor, Benzodiazepine,Receptor, Benzodiazepine-GABA,Receptor, Diazepam,Receptor, GABA-A,Receptor, GABA-Benzodiazepine,Receptor, Muscimol,Receptors, Benzodiazepine GABA,Receptors, GABA A,Receptors, GABA Benzodiazepine,delta Subunit, GABA A Receptor,epsilon Subunit, GABA A Receptor,gamma Aminobutyric Acid Subtype A Receptors
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077334 Zolpidem An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA. Imidazo(1,2-a)pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-,Ambien,Amsic,Bikalm,Dalparan,N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2a)pyridine-3-acetamide hemitartrate,SL 80.0750,SL-800750-23-N,Stilnoct,Stilnox,Zodormdura,Zoldem,Zolirin,Zolpi-Lich,Zolpidem 1A Pharma,Zolpidem AbZ,Zolpidem Hemitartrate,Zolpidem Tartrate,Zolpimist,Zolpinox,SL 800750 23 N,Zolpi Lich
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Enrico Sanna, and Fabio Busonero, and Giuseppe Talani, and Mario Carta, and Federico Massa, and Michela Peis, and Elisabetta Maciocco, and Giovanni Biggio
June 2000, Journal of clinical psychopharmacology,
Enrico Sanna, and Fabio Busonero, and Giuseppe Talani, and Mario Carta, and Federico Massa, and Michela Peis, and Elisabetta Maciocco, and Giovanni Biggio
July 1991, Brain research,
Enrico Sanna, and Fabio Busonero, and Giuseppe Talani, and Mario Carta, and Federico Massa, and Michela Peis, and Elisabetta Maciocco, and Giovanni Biggio
January 1992, Psychopharmacology,
Enrico Sanna, and Fabio Busonero, and Giuseppe Talani, and Mario Carta, and Federico Massa, and Michela Peis, and Elisabetta Maciocco, and Giovanni Biggio
September 2005, Dentistry today,
Enrico Sanna, and Fabio Busonero, and Giuseppe Talani, and Mario Carta, and Federico Massa, and Michela Peis, and Elisabetta Maciocco, and Giovanni Biggio
October 2006, Journal of toxicology and environmental health. Part A,
Enrico Sanna, and Fabio Busonero, and Giuseppe Talani, and Mario Carta, and Federico Massa, and Michela Peis, and Elisabetta Maciocco, and Giovanni Biggio
October 1996, European journal of pharmacology,
Enrico Sanna, and Fabio Busonero, and Giuseppe Talani, and Mario Carta, and Federico Massa, and Michela Peis, and Elisabetta Maciocco, and Giovanni Biggio
August 1994, British journal of pharmacology,
Enrico Sanna, and Fabio Busonero, and Giuseppe Talani, and Mario Carta, and Federico Massa, and Michela Peis, and Elisabetta Maciocco, and Giovanni Biggio
November 1997, Behavioural pharmacology,
Enrico Sanna, and Fabio Busonero, and Giuseppe Talani, and Mario Carta, and Federico Massa, and Michela Peis, and Elisabetta Maciocco, and Giovanni Biggio
September 1999, British journal of clinical pharmacology,
Enrico Sanna, and Fabio Busonero, and Giuseppe Talani, and Mario Carta, and Federico Massa, and Michela Peis, and Elisabetta Maciocco, and Giovanni Biggio
July 1999, Psychopharmacology,
Copied contents to your clipboard!